Clinical trials: Prednisone, completed
Prostatic Neoplasms
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
- Trial name
- NCT00137436
- Testing
- Docetaxel, Prednisone, SU011248
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Pfizer
Esophageal Stenosis Acquired
Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma
Endoscopic submucosal dissection as the fastest growing endoscopic treatment technology in the past decade has been widely used in the treatment of early esophageal cancer and gastric cancer without local lymph node metastasis.
- Trial name
- NCT03165344
- Testing
- Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration), Triamcinolone Acetonide (route of administration), Prednisone (route of administration)
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University Third Hospital
Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT01792687
- Testing
- ARN-509, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Covid19
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
This study looks at the safety and effectiveness of Aviptadil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- NCT06729606
- Testing
- Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 471 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone…
- Trial name
- NCT00877006
- Testing
- bendamustine, rituximab, vincristine
- Where
- 128 sites in United States, Australia and 5 more
- Volunteers
- 447 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Lymphoma
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00070447
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 87 sites in United States, Australia and 3 more
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to see what effects (good and bad) treatment with abiraterone acetate (an oral hormonal agent) and prednisone (a steroid) with and without cabazitaxel (a chemotherapy) have on the cancer and to find…
- Trial name
- NCT02218606
- Testing
- Abiraterone acetate 1000 mg po daily, Cabazitaxel 25 mg/m2 IV, prednisone 5 mg po BID
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
The primary objective was to compare the progression-free survival of transplant ineligible patients newly diagnosed with multiple myeloma who were treated with carfilzomib, melphalan and prednisone (CMP) or with Velcade®…
- Trial name
- CLARION (NCT01818752)
- Testing
- Carfilzomib, Bortezomib, Melphalan
- Where
- 213 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Amgen
Prostate Cancer
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Primary Objective: To assess effectiveness of prophylactic treatment of hematological complications (grade ≥ 3 neutropenia) resulting from cabazitaxel treatment for 21 days after treatment initiation.
- Trial name
- PROSPECTA (NCT01649635)
- Testing
- CABAZITAXEL (XRP6258), Prednisone, Ciprofloxacin
- Where
- 6 sites in Brazil
- Volunteers
- 45 people
- Sponsor
- Sanofi
Severe Persistent Asthma, Eosinophilic Bronchitis
Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
The steroid sparing effect of anti interleukin (IL-5) monoclonal antibody has been proven, but the effectiveness of subcutaneous (SC) compared to intravenous (IV) administration of these drugs to suppress airway eosinophilia is…
- Trial name
- NCT02559791
- Testing
- Reslizumab
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
RSV Infection
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects
- Trial name
- NCT03750383
- Testing
- EDP-938, Cyclosporine, Prednisone
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Upper Respiratory Tract Infection, Asthma
Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia
The purpose of this study is to investigate the benefits of giving filled prescription of a medication to be used upon early onset of symptoms of URTI induced asthma.
- Trial name
- NCT01326494
- Testing
- Arm 1 Oral Cortico Steroids
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- University of British Columbia
Healthy
Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits
The purpose of this study is to see if a medication taste test influences the prescribing habits of pediatric prescribers at Mayo Clinic.
- Trial name
- NCT01734759
- Testing
- Taste Test
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Diffuse Large B-Cell Lymphoma, POOR PROGNOSIS
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
The purpose of this trial was to evaluate efficacy and safety of adding Rituximab to dose-dense and High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as first line treatment in young patients with…
- Trial name
- DLBCL (NCT00556127)
- Testing
- Rituximab, Epirubicin, Cyclophosphamide
- Where
- 14 sites in Italy
- Volunteers
- 94 people
- Sponsor
- Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Transplant Rejection, Kidney Transplantation
Study of Tolerant Kidney Transplant Recipients
The purpose of this multi-center (observational) registry study is to establish a database of clinical and laboratory information that may help to identify any unique characteristics of tolerant participants that differ from…
- Conditions
- Transplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant
- Trial name
- FACTOR (NCT01338779)
- Where
- 4 sites in United States
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prostatic Neoplasms, Prostate Cancer
AMG 386 and Abiraterone for Advanced Prostate Cancer
Background: Advanced prostate cancer is treated with surgery or drugs that lower the levels of androgens (male hormones) in the body. However, some cancers become resistant to this treatment.
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Neoplasm, Prostate, Neoplasm,Prostatic
- Trial name
- NCT01553188
- Testing
- AMG 386, Abiraterone, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
End-stage Renal Disease, Renal Transplantation
Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a relative with the same (or nearly the same) blood cell type as the transplant recipient.
- Conditions
- End-stage Renal Disease, Renal Transplantation, Kidney Transplantation
- Trial name
- NCT00063817
- Testing
- Conditioning Regimen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with more than one drug regimen may kill more tumor cells.
- Trial name
- NCT00003215
- Testing
- filgrastim, CHOP regimen, cyclophosphamide
- Where
- 12 sites in Austria, Germany and 3 more
- Volunteers
- 400 people
- Sponsor
- Swiss Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.